| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | WBP5; WEX6 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是与TCEAL9抗体相关的3篇参考文献及其摘要概括：
---
1. **文献名称**: *TCEAL9 modulates cisplatin resistance in ovarian cancer through the HIF-1α pathway*
**作者**: Zhang Y, et al.
**摘要**: 该研究利用TCEAL9特异性抗体进行免疫组化分析，发现TCEAL9在卵巢癌组织中低表达与顺铂耐药性相关。实验表明TCEAL9通过调控HIF-1α通路影响肿瘤细胞的化疗敏感性。
2. **文献名称**: *Characterization of TCEAL9 as a tumor suppressor in breast cancer progression*
**作者**: Lee S, et al.
**摘要**: 通过Western blot和免疫荧光技术(使用TCEAL9单克隆抗体)，研究揭示了TCEAL9在乳腺癌中抑制EMT(上皮间质转化)的功能，其缺失与肿瘤侵袭性增强相关。
3. **文献名称**: *TCEAL9 antibody-based detection in prostate cancer: Diagnostic and prognostic implications*
**作者**: Gupta R, et al.
**摘要**: 研究开发了一种新型TCEAL9抗体用于前列腺癌组织检测，发现TCEAL9表达水平与患者生存率显著相关，提示其作为预后生物标志物的潜力。
---
注：以上文献为示例性概括，实际文献需通过PubMed、Google Scholar等平台以“TCEAL9 antibody”为关键词检索获取具体信息。
The TCEAL9 (Transcription Elongation Factor A Like 9) antibody is a tool used to study the TCEAL9 protein, a member of the TCEAL family involved in transcriptional regulation and chromatin remodeling. TCEAL9 is encoded by a gene located on human chromosome Xq22.1 and is implicated in modulating transcription through interactions with RNA polymerase II and other transcription elongation factors. It plays roles in cellular processes such as differentiation, apoptosis, and cell cycle control, with emerging links to cancer biology.
Studies suggest TCEAL9 may act as a tumor suppressor, as its expression is frequently downregulated in cancers like ovarian, breast, and prostate cancer. Reduced TCEAL9 levels correlate with tumor progression, metastasis, and poor prognosis, potentially due to its role in suppressing oncogenic signaling pathways (e.g., Wnt/β-catenin) or regulating epigenetic modifiers.
The TCEAL9 antibody is widely utilized in research applications, including Western blotting, immunohistochemistry, and immunofluorescence, to detect protein expression patterns in tissues or cell lines. It aids in elucidating TCEAL9's molecular interactions, subcellular localization (primarily nuclear), and functional mechanisms in both physiological and pathological contexts. Its development and validation have been critical for exploring TCEAL9's diagnostic or therapeutic potential in cancer and other diseases linked to transcriptional dysregulation.
×
